首页> 美国卫生研究院文献>other >Pioglitazone Treatment Increases Survival and Prevents Body Weight Loss in Tumor–Bearing Animals: Possible Anti-Cachectic Effect
【2h】

Pioglitazone Treatment Increases Survival and Prevents Body Weight Loss in Tumor–Bearing Animals: Possible Anti-Cachectic Effect

机译:吡格列酮治疗可增加存活率并防止荷瘤动物体重减轻:可能的抗恶病质作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cachexia is a multifactorial syndrome characterized by profound involuntary weight loss, fat depletion, skeletal muscle wasting, and asthenia; all symptoms are not entirely attributable to inadequate nutritional intake. Adipose tissue and skeletal muscle loss during cancer cachexia development has been described systematically. The former was proposed to precede and be more rapid than the latter, which presents a means for the early detection of cachexia in cancer patients. Recently, pioglitazone (PGZ) was proposed to exhibit anti-cancer properties, including a reduction in insulin resistance and adipose tissue loss; nevertheless, few studies have evaluated its effect on survival. For greater insight into a potential anti-cachectic effect due to PGZ, 8-week-old male Wistar rats were subcutaneously inoculated with 1 mL (2×107) of Walker 256 tumor cells. The animals were randomly assigned to two experimental groups: TC (tumor + saline-control) and TP5 (tumor + PGZ/5 mg). Body weight, food ingestion and tumor growth were measured at baseline and after removal of tumor on days 7, 14 and 26. Samples from different visceral adipose tissue (AT) depots were collected on days 7 and 14 and stored at -80o C (5 to 7 animals per day/group). The PGZ treatment showed an increase in the survival average of 27.3% (P< 0.01) when compared to TC. It was also associated with enhanced body mass preservation (40.7 and 56.3%, p< 0.01) on day 14 and 26 compared with the TC group. The treatment also reduced the final tumor mass (53.4%, p<0.05) and anorexia compared with the TC group during late-stage cachexia. The retroperitoneal AT (RPAT) mass was preserved on day 7 compared with the TC group during the same experimental period. Such effect also demonstrates inverse relationship with tumor growth, on day 14. Gene expression of PPAR-γ, adiponectin, LPL and C/EBP-α from cachectic rats was upregulated after PGZ. Glucose uptake from adipocyte cells (RPAT) was entirely re-established due to PGZ treatment. Taken together, the results demonstrate beneficial effects of PGZ treatment at both the early and final stages of cachexia.
机译:恶病质是一种多因素综合症,其特征是严重的非自愿体重减轻,脂肪消耗,骨骼肌消瘦和虚弱无力。所有症状均不完全归因于营养摄入不足。已经系统地描述了癌症恶病质发展期间的脂肪组织和骨骼肌损失。提出前者要比后者快,并且要比后者快,后者为癌症患者早期发现恶病质提供了一种手段。最近,吡格列酮(PGZ)被提议具有抗癌特性,包括降低胰岛素抵抗和脂肪组织损失。但是,很少有研究评估其对生存的影响。为了更深入地了解PGZ可能产生的抗恶病质作用,对1周(2×10 7 )Walker 256肿瘤细胞皮下接种8周大的雄性Wistar大鼠。将动物随机分为两个实验组:TC(肿瘤+生理盐水对照)和TP5(肿瘤+ PGZ / 5 mg)。在基线,切除肿瘤后第7、14和26天测量体重,食物摄入和肿瘤生长。在第7和14天收集不同内脏脂肪组织(AT)库的样品,并在-80o C下保存(5每天/每组7只)。与TC相比,PGZ治疗的生存率平均提高了27.3%(P <0.01)。与TC组相比,在第14天和第26天,它还具有增强的体重保存(40.7和56.3%,p <0.01)。在晚期恶病质期间,与TC组相比,该治疗还减少了最终肿瘤块(53.4%,p <0.05)和厌食。在同一实验期间,与TC组相比,腹膜后AT(RPAT)质量在第7天得以保留。在第14天,这种作用还证明与肿瘤生长成反比关系。PGZ后,来自恶病质大鼠的PPAR-γ,脂联素,LPL和C /EBP-α的基因表达上调。由于PGZ处理,脂肪细胞(RPAT)的葡萄糖吸收得以完全恢复。两者合计,结果表明PGZ治疗在恶病质的早期和最终阶段均有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号